HR Execs on the Move

Vernalis

www.vernalis.com

 
Vernalis plc is a revenue generating development stage pharmaceutical company with one marketed product, frovatriptan, and a broad pipeline of research and development programmes. The business model is a balance between risk and innovation with the aim of creating value through a focused and disciplined strategy. An exclusive development and licensing agreement with Tris Pharma to develop multiple novel products focussed on the US prescription cough cold market is the platform for Vernalis to build a profitable and cash generative commercial business in the US. These novel products are low risk, late stage and differentiated for an unmet need. Value ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.vernalis.com
  • 1000 Westlakes Drive Suite 200
    Berwyn, PA USA 19312
  • Phone: 484.913.0700

Executives

Name Title Contact Details

Similar Companies

Advanced Pipetting Systems

Advanced Pipetting Systems is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Monitored Therapeutics

Monitored Therapeutics Inc. is focused on solutions for the management of respiratory diseases like COPD, Asthma, Lung Transplant, and Cystic Fibrosis.

Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company`s global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (Florida). The Company focusses on “difficult to manufacture” products that are sold in over 100 countries.

Nesher Pharmaceuticals

BrainStorm Cell

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to over 50 patients with ALS in clinical trials conducted in Israel and the United States, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.